Home›Ganciclovir›Ganciclovir + Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox

Does Ganciclovir Interact with Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox?

Ganciclovir and Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox have a moderate drug interaction according to U.S. FDA drug labeling data. Ganciclovir is eliminated by active tubular secretion; coadministration may increase concentrations of ganciclovir and emtricitabine/tenofovir, increasing risk of adverse reactions. The mechanism involves competition for active tubular secretion in kidneys. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity: Moderate
Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox Class: Cytochrome P450 3A Inhibitor
Management: Monitor for effects
Data Source: U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Ganciclovir and Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox occurs because competition for active tubular secretion in kidneys. Clinically, this means ganciclovir is eliminated by active tubular secretion; coadministration may increase concentrations of ganciclovir and emtricitabine/tenofovir, increasing risk of adverse reactions. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.

What To Tell Your Doctor or Pharmacist

If you are taking Ganciclovir and your doctor is considering prescribing Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Ask whether any dosage adjustments are needed
Never stop or change either medication without first consulting your healthcare provider

💊 Ganciclovir(Zirgan)+💊 Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox(Stribild)

Severity & Interaction Details

🟡

moderate

Be aware — moderate interaction

Documented interaction with manageable risk. May require dose adjustment or monitoring.

Severity scale

MinorContra

On record

Yes

Drug A class

—

Drug B class

Cytochrome P450 3A Inhibitor

Source

NLP:elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate

What this means in plain English

Ganciclovir is eliminated by active tubular secretion; coadministration may increase concentrations of ganciclovir and emtricitabine/tenofovir, increasing risk of adverse reactions.

About Ganciclovir and Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox

Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox is a Cytochrome P450 3A Inhibitor. You may recognize them by the brand names Zirgan and Stribild. Ganciclovir is given by intravenous (IV) infusion, whereas Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox is taken by mouth. Both Ganciclovir and Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox carry an FDA boxed warning — the agency's most serious safety designation.

What the FDA label says

"Competition for active tubular secretion in kidneys"

📖 Source: NLP:elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

FDA

FDA Safety Alert: Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg, 100-count bottle, Rx Only,about Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox · 2026-02

PubMed

A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.about Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox · 2018-10

PubMed

Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.about Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox · 2017-07

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Ganciclovir and Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.